efficacy of Fumitory in chronic urticaria

Comparison the Efficacy of an edible product of Fumitory, a traditional Iranian formula, with Cetirizine in Treatment of chronic Urticaria

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015112825275N1

Enrollment

Registered

2016-02-26

Start date

2016-01-05

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic urticaria. Other urticaria Urticaria: chronic recurrent periodic

Interventions

Intervention 1: Intervention group: receiving orally fumitory syrup twice a day, each time 10 cc for one month. Intervention 2: Control group: receiving orally Cetirizine syrup twice a day, ea

Treatment - Drugs

Intervention group: receiving orally fumitory syrup twice a day, each time 10 cc for one month

Control group: receiving orally Cetirizine syrup twice a day, each time 10 cc for one month l

Eligibility

Sex/Gender

All

Age

12 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with chronic urticaria with doctor confirmation, 12 to 70 years old, male and female, have tendency for entering into study Exclusion criteria: Using topical corticosteroid during the past week, Using oral corticosteroid during the past week, using antihistamines within last four days, pregnancy & Breast-feeding, having severe angioedema, having uncontrolled cardiovascular, respiratory , hematologic, urology, immune system & Connective tissue diseases, having sensitivity to Cetirizine, having sensivity to fumitory plant, history of Seizure, history of rising intraocular pressure, incidence of side effects, Unwillingness to continue this study; Unable to follow up the patient regularly

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Quantity of hives. Timepoint: The First,third and fourth weeks of study. Method of measurement: Urticaria Activity Score (UAS) questionnaire.;Level of itch. Timepoint: The First, Third and fourth weeks of study. Method of measurement: Urticaria Activity Score (UAS) questionnaire.;Quality of life. Timepoint: The First,third and fourth weeks of study. Method of measurement: Quality of Life Questionnaire of chronic urticaria CU-Q2oL.	—

Measure

Time frame

Quantity of hives. Timepoint: The First,third and fourth weeks of study. Method of measurement: Urticaria Activity Score (UAS) questionnaire.;Level of itch. Timepoint: The First, Third and fourth weeks of study. Method of measurement: Urticaria Activity Score (UAS) questionnaire.;Quality of life. Timepoint: The First,third and fourth weeks of study. Method of measurement: Quality of Life Questionnaire of chronic urticaria CU-Q2oL.

—

Secondary

Measure	Time frame
Side effects. Timepoint: The first, third and fourth weeks of study. Method of measurement: common Terminology Criteria for Adverse Events v4.0 2009 questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Eghbalian

Tehran university of medical science

f-eghbalian@razi.tums.ac.irdreghbalian@gmail.com+98 21 2298 8551

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026